Issue: November 2017
Perspective from Ben N Fogel, MD MPH
November 21, 2017
3 min read
Save

Influenza vaccination rates unchanged after ACIP withdraws LAIV recommendation

Issue: November 2017
Perspective from Ben N Fogel, MD MPH
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Although the Advisory Committee on Immunization Practices no longer recommends the live-attenuated influenza vaccine, or LAIV, overall child influenza immunization rates remained unchanged between the 2015-2016 and 2016-2017 influenza seasons, according to a study published in Pediatrics.

In addition, researchers observed that children who had previously received an injectable influenza vaccine (IIV) were slightly more likely to return for immunizations the following year compared with children who had received LAIV.

The ACIP recommended against using LAIV in June 2016 after research showed it was less effective than the injectable vaccine in preventing the H1N1 strain of influenza. As a nasal spray, LAIV was a less painful and more convenient option for young children.

“A motivating concern for this study was that the withdrawal of the LAIV recommendation would lower childhood influenza immunization rates and that further interventions might be needed to promote the use of the injectable influenza vaccines among parents who in previous seasons had opted to use an LAIV,” Steve G. Robison, MPH, from the immunization program at the Oregon Heath Authority, and colleagues wrote.

The researchers compared child immunization rates from the 2012-2013 season with those from the 2016-2017 season using data from Oregon’s statewide immunization registry.

Children were additionally matched in groups and selected based on whether they received LAIV or an IIV in the 2015-2016 season. The researchers assessed whether these children returned for IIV in the 2016-2017 season.

For children aged 2 to 17 years, influenza immunization rates remained consistent across the 2015-2016 and 2016-2017 seasons. If a child between the ages of 3 and 10 years had previously received IIV, they were 1.03 times (95% CI, 1.02-1.04) more likely to receive IIV in the 2016-2017 season than children who were previously vaccinated with LAIV. Children aged 11 to 17 years who were previously immunized with IIV were 1.08 times (95% CI, 1.05 to –1.09) more likely than those who received an LAIV to return for immunization.

Research thus far has been somewhat inconsistent about whether the ACIP’s decision to recommend against LAIV has had an impact on vaccine uptake among children. In a recent study of almost 10,000 Penn State Pediatric patients, researchers saw a small but statistically significant drop — 1.6% — in end-of-season influenza vaccination rates after LAIV was no longer recommended by the CDC. – by Katherine Bortz

Disclosures: The authors report no relevant financial disclosures.